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Abstract 
How to use inotropes is one of the most controversial topics in the management 
of heart failure.  While most clinicians use these drugs, and recognize the state of 
inotrope dependency, current guidelines recommend them onlu as a bridge or 
palliation. Thus, inotropes are considered either neutral or detrimental in terms of 
outcomes. Meanwhile, properly designed randomized clinical trials testing the 
outcomes on inotropes, have never been performed and it is unlikely that they 
will ever be attempted. These trials would require randomizing patients with 
advanced heart failure, low output syndrome, and impaired end-organ perfusion 
into groups that received or not received inotropes, or received inotropes or 
placebo. Many physicians would consider this design unethical so the trials 
would be challenging to implement. But if it is unethical to deny inotropes to this 
subset of patients, we have to admit that inotropes do not only improve quality of 
life, but prolong it, or decrease mortality. Otherwise, we consider it unethical to 
deny the medication which increases mortality.  
 
In this review, we analyze the current evidence relating to inotropes and 
outcomes. We demonstrate that the original trials were performed with agents 
that are no longer in use, or on patients without an indication for inotropes, or at a 
time before automatic cardio-defibrillators were recommended for primary 
prevention.  We conclude that current guidelines for inotropes are misleading in 
their interpretation of outcomes in patients with advanced heart failure. The 
guidelines should be revised to adequately reflect the evidence.  
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Introduction 
 The role of inotropes in management of heart failure (HF) is changing. 
Mechanical circulatory support (MCS) offers increased survival and improved 
quality of life, far beyond the potential of inotropes. Nevertheless, many 
cardiologists still use them. It is much easier for the patient to accept continuous 
intravenous infusion of another drug, than to agree to an open heart surgery with 
implantation of hardware which requires serious maintenance and chronic 
anticoagulation. With rare exceptions, the left ventricular assist device (LVAD) 
implant is irreversible. Unlike medicine, it changes the lifestyle for a long time, till 
heart transplant, or forever. To the contrary, being on an inotrope is much less 
demanding. Because so many patients still remain on inotropes for months or 
even years, we want to clarify the issue of increased mortality, linked to the 
inotrope use. 
 At present, the use of inotropic agents in the management of HF is 
controversial.  On one hand, specialists who manage  patients with advanced HF 
utilize  them widely.  The Acute Heart Failure Global Survey of Standard 
Treatment (ALARM-HF) global survey of 666 hospitals in nine countries showed 
that inotropes were used in 39% of all admissions for acute HF 1.  In the 
Randomized Evaluation of Mechanical Assistance for the Treatment of 
Congestive Heart Failure (REMATCH) trial, 72% of patients in the medical arm 
and 65% of patients in the ventricular assist device arm were on inotropes 2. 
Indeed, the HF community uniformly recognizes the state of “inotrope 
dependency”. On the other hand, current guidelines caution that these drugs may 
be potentially detrimental: “Despite improving hemodynamic compromise, 
positive inotropic agents have not demonstrated improved outcomes in patients 
with HF in either the hospital or outpatient setting” 3.   
Current Guidelines on Inotropes 
Guidelines of the American College of Cardiology Foundation/American Heart 
Association (ACCF/AHA) (2013)3, Heart Failure Society of America (2010) 4, 
European Society of Cardiology (2012) 5, and International Society for Heart and 
Lung Transplantation 6-8 have recommendations on inotropes in HF. The 
recommendations of various societies are summarized in Table 1. In general, 
inotropes are indicated in the presence of acute or chronic hemodynamic 
compromise with end organ dysfunction due to low output, and are considered to 
be detrimental and contraindicated if this syndrome is not present. 
Specifically, the ACCF/AHA guidelines state that use of parenteral inotropic 
agents in hospitalized patients without documented severe systolic dysfunction, 
low blood pressure, or impaired perfusion, and evidence of significantly 
depressed cardiac output, with or without congestion, is potentially harmful 3.  
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These recommendations are based on profound understanding on 
pathophysiology of HF. As the disease progresses over time, the heart maintains 
normal cardiac output, but at the cost of rising left ventricular end diastolic 
pressure (Figure 1). The mainstay intervention at these stages is diuretic therapy, 
which decreases intracardiac filling pressures (congestion), along with 
medications favoring left ventricular reverse remodeling such as angiotensin 
converting enzyme inhibitors. Eventually, compensatory mechanisms fail, and 
cardiac output decreases. Only at this advanced stage, inotropes can be 
beneficial. Because low output is not present at the earlier stages, administration 
of inotropes cannot be favorable but can certainly cause harm because of side 
effects.   
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Figure 1. Hemodynamics in Heart Failure: a Progression (from Barry Borlaug, 
with permission) 
 
Inotropes: Hemodynamic Effects 
Milrinone and dobutamine are currently the only two inotropes approved for use 
in the United states and both exert their actions by increasing the intracellular 
level of cyclic adenosine monophosphate 9.  Dobutamine achieves this effect 
indirectly through adrenergic agonism while milrinone, a phosphodiesterase 
inhibitor, directly blocks cyclic monophosphate breakdown 10. We reviewed the 
mechanism of action of both drugs in previously published paper 11. 
 
Page 3A 
Table 1. Guideline recommended indications for inotropic agents in heart failure 
Guidelines  Strength Level of 
Evidenc
e  
American College of 
Cardiology 
Foundation/American 
Heart Association 
20133   
Cardiogenic shock, until definitive therapy (e.g., coronary revascularization, MCS, 
heart transplantation) or resolution of the acute precipitating problem  
I C 
  “Bridge therapy” in stage D refractory to guideline determined medical therapy and 
device therapy, while awaiting MCS or cardiac transplantation 
IIA B 
 Severe systolic dysfunction with low blood pressure and significantly depressed 
cardiac output in hospitalized patients  
IIB B 
 Palliative therapy for symptom control in select patients with stage D despite optimal 
guideline determined therapy, not eligible for either MCS or cardiac transplantation   
IIB B 
 Long-term IV inotropes, in the absence of specific indications or for reasons other 
than palliative care, are potentially harmful  
III B 
 Inotropes in hospitalized patients without severe systolic dysfunction, low blood 
pressure, or impaired perfusion, and evidence of significantly depressed cardiac 
output, with or without congestion, is potentially harmful .   
III B 
European Society of 
Cardiology 2012 5 
Inotropes should be considered in patients with hypotension (systolic blood pressure 
<85 mmHg) and/or hypoperfusion    
IIA C 
 Inotropes are NOT recommended unless there is hypotension (systolic blood 
pressure <85 mmHg), hypoperfusion, or shock because of safety concerns (atrial 
and ventricular arrhythmias, myocardial ischaemia, and death). 
III C 
Heart Failure Society 
of America 2010  4 
 
IV inotropes may be considered to relieve symptoms and improve end-organ 
function in HF with LV dilation, reduced LVEF, and diminished peripheral perfusion 
or end-organ dysfunction (low output syndrome), particularly if systolic blood 
pressure is <90 mm Hg, in symptomatic hypotension despite adequate filling 
pressure, or unresponsiveness/intolerance of IV vasodilators. 
may be 
consi- 
dered 
C 
 Inotropes may be considered in similar patients with evidence of fluid overload if 
they respond poorly to IV diuretics or have diminished/ worsening renal function.  
may be 
consi- 
dered 
C 
 IV inotropes are not recommended unless left heart filling pressures are elevated or 
cardiac index is severely impaired  
not re-
commen- 
ded 
C 
International Society 
for Heart and Lung 
Transplantation 2006 6  
In patients with decompensated HF and hypoperfusion in spite of adequate filling 
pressures, inotropic or pressor therapy should be used. 
  
I C 
 Long-term use of inotropic therapy should only be used as a pharmacologic bridge 
to transplantation or for palliation. 
I C 
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The magnitude of hemodynamic effects of the inotropes on cardiac index and 
cardiac output is remarkable.  Insurance carriers look for a 20% increase in 
cardiac index or a similar decrease in pulmonary wedge pressure, in order to 
issue an approval for continuous home inotropes 12. However, greater response 
is common, with a twofold increase in cardiac index commonly observed 13.  
Milrinone in currently approved doses typically increases cardiac index by 24- 
42%, decreases pulmonary capillary wedge pressure by 24- 33%, and reduces 
systemic vascular resistance by 15- 31%, with dose-dependent effect.  The drug 
is effective in most patients, and those with the worst hemodynamic profile at 
baseline derived the most benefits 12.   
 
Most of hemodynamic effects of dobutamine and milrinone are similar 14. Both 
dobutamine and milrinone 
 
 Increase cardiac output 
 Cause peripheral vasodilation 
 Decrease pulmonary capillary wedge pressure 
 
There are some differences between dobutamine and milrinone 15-18 
 
Dobutamine, in comparison with milrinone, causes 
 Greater increase in heart rate    
 Greater increase in myocardial oxygen consumption   
 Greater proarrhythmic effect, including ventricular tachycardia  19,20 
 Effects are attenuated in patients who receive beta blockers 
 
Milrinone, in comparison with dobutamine, causes 
 More hypotension   
 Greater reduction in left and right heart filling pressures   
 Greater reduction in mean arterial pressure 
 Greater reduction in pulmonary arterial pressure 
 Longer duration of action after discontinuation of the drip, 
especially in the presence of renal dysfunction 
 Greater hemodynamic effects in general when the patient is on 
beta blockers 
 
In direct comparison of dobutamine and milrinone, Colucci et al.17 found that 
milrinone caused a significantly greater reduction in left and right heart filling 
pressures and mean arterial pressure than did dobutamine, and for any given 
increase in dP/dt, milrinone caused a greater reduction in systemic vascular 
resistance than did dobutamine. Hemodynamic effects of dobutamine were 
blunted in patients with severe HF and elevated serum norepinephrine, most 
likely due to desensitization of myocardial beta 1 adrenoreceptors. 
The biggest difference between the two especially in our expanding health care 
system may be cost.  Dobutamine is cheaper 21,22. For a course of in-hospital 
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inotrope therapy, total acquisition cost of milrinone was significantly higher than 
that of dobutamine (16,270 dollars +/- 1334 versus 380 dollars +/- 533 P 
<.00001)21.  In terms of arrhythmogenicity, dobutamine causes atrial and 
ventricular arrhythmias more commonly than milrinone, although both agents 
have proarrhythmic potential and hence both require continuous rhythm 
monitoring, at least while in the hospital. Milrinone causes nonsustained 
ventricular tachycardia in 3.7% of patients and sustained ventricular tachycardia 
in 0.5% 12. 
Overall, hemodynamic properties of inotropes seem to be optimal for low output, 
or “cold” HF patients, especially if they are also “wet”23, i.e. have volume overload 
and increased intracardiac pressures. It is well known that this type of HF 
patients has the worst prognosis 24. Besides, increase in cardiac output and 
decrease in congestion frequently results in improved urine output, a 
phenomenon widely known to HF doctors 16,25. 
It is quite counterintuitive that drugs with such remarkable hemodynamic effects 
can be detrimental in advanced HF. 
Table 2. Properties of dobutamine and milrinone 
Inotrope Dose Onset and 
Duration of 
action 
Side effects 
Dobutamine 2.5 to 20 
μg/kg/min IV 
 
Onset of action 
is 1 to 10 min, 
peak effect 10 
to 20 min. The 
half-life is 2 
min 
Ventricular ectopy, 
tachycardia, 
hypotension, angina, 
palpitations, fever, 
headache, nausea 
Milrinone 0.25 to 0.75 
μg/kg/min IV  
Onset of action 
is 5 to 15 min. 
The half-life is 
2.5 hours 
Ventricular and 
supraventricular 
arrhythmias, angina, 
hypotension, headache 
 
 
Inotrope Dependency 
 
The term “inotrope-dependent” is used liberally in the guidelines, without a formal 
definition. Patients are characterized as inotrope dependent if they cannot be 
weaned off inotropes at an experienced HF center 4. Inotrope dependence 
means that withdrawal of inotropes leads to symptomatic hypotension, recurrent 
congestive symptoms, or worsening renal function 26. It is recognized that 
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symptoms and not purely the values of re-measured hemodynamic parameters 
have to be considered when deciding on inotrope dependence 26.   
The inotrope dependency is particularly important when determination of the 
need for advanced HF therapies such as heart transplantation or ventricular 
assist device. Profile one, or “crush and burn”, includes patients who rapidly 
decline despite inotropes, profile two patients decline more gradually but still 
“Sliding on inotropes.” Profile three  includes most stable patients who still need 
to be on inotropes, with the description  “stable blood pressure, organ function, 
nutrition, and symptoms on continuous intravenous inotropic support (or a 
temporary circulatory support device or both), but demonstrating repeated failure 
to wean from support due to recurrent symptomatic hypotension or renal 
dysfunction: “dependent stability.”27 
 
The HFSA guidelines state that “these agents may help relieve symptoms due to 
poor perfusion and preserve end-organ function in patients with severe systolic 
dysfunction and dilated cardiomyopathy”4 End organ function in HF is usually 
related to hepatic and renal function. If inotropes help preserve liver and kidney 
function, they ought to prolong life, or to “avoid imminent death”28. The best 
definition of inotrope dependency we found in the paper by Hershberger et al.28: 
“Inotropic dependence was defined as the failure to wean from inotropes 
because of imminent (minutes to hours) worsening of the patient’s clinical status 
(combined objective [eg, blood pressure, level of consciousness, confusion, 
change in creatinine, oxygenation] and subjective [eg, dyspnea, confusion, 
weakness]), such that death appeared imminent, and the patient was deemed 
highly unlikely to survive inotrope withdrawal to permit hospital discharge”. The 
authors state further that the attempted withdrawal of inotropic support in this 
cohort of patients can be acutely life-threatening 28. 
 
If we recognize that patients on inotropes cannot be weaned off of them, we have 
to admit that inotropes reduce mortality in this terminal end stage HF population. 
Otherwise, the term “inotrope dependent” becomes oxymoranical. 
 
Inotrope dependency is the condition, which makes it unfeasible and ethically 
unacceptable to conduct any randomized controlled trials on inotropes versus 
placebo or inotrope versus no inotrope. The only comparison possible is one 
inotrope versus another, or inotropes versus a different mean of inotropic 
support, like in the REMATCH (Randomized Evaluation of Mechanical 
Assistance for the Treatment of Congestive Heart Failure) trial 2. Indeed, Lynne 
Stevenson wrote in 2003 16 that randomized trials performed with and without 
inotropic infusions during HF hospitalizations have selected patients in whom 
intravenous therapy was not considered essential for management. Hershberger 
et al. also wrote that a randomized clinical trial designed to remove dobutamine 
from patients deemed inotrope-dependent would cause considerable discomfort 
from an ethical perspective 28. Ten years later, this statement still holds true. But 
if you enroll only patients in whom the intervention is not essential, you cannot 
establish the value of the very intervention that is tested.      
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Patterns of Inotrope Use 
There are three distinct patterns of intravenous inotrope use: confined to hospital 
admission, intermittent home infusions (usually several times per week at the 
infusion center), and the infusions started in the hospital and continued at home 
continuously, weeks to months and even years in duration. In the past, some 
inotropes were also used orally in the outpatient setting. Below, we briefly 
summarize non-randomized studies based on the setting of infusion. The studies 
where patients were randomized into inotrope versus placebo or inotrope versus 
no inotrope, regardless of the setting where infusion was performed, are 
summarized in Tables 3-5 in the end of the manuscript. All studies, in the text 
and in the table, include patients with symptomatic HF and decreased left 
ventricular ejection fraction. 
Hospital Infusions 
 Some studies report the experience with in-hospital inotrope 
infusions when the patients were admitted not because of 
hemodynamic compromise and low output syndrome, but 
electively. A three-day dobutamine infusion in 29 patients resulted 
in hemodynamic and metabolic improvement, including elevation 
of sodium and improvement in renal function 29    
  Intravenous milrinone given to 14 patients resulted in improved 
hemodynamics and allowed higher doses of diuretics and other 
HF medications. Oral angiotensin-converting enzyme inhibitor and 
diuretic doses were increased by 318% and 89%, respectively. 
NYHA functional class improved from 3.8 +/- 0.4 to 2.6 +/- 0.6 
following therapy, and there was a reduction in hospital 
admissions in 10 patients who responded to therapy during the 
subsequent year compared with the year before treatment (4 +/- 
17 versus 17 +/- 15) 30.   
 Intermittent infusions of either dobutamine (43 
patients) or nitroprusside was given to a total of 113 patients for 
about a month. There was a higher re-hospitalization rate (86% 
versus 57%, p<0.02) and higher mortality (58% versus 28%) in the 
dobutamine group. The decision of using dobutamine versus 
nitroprusside was made by individual physicians. Baseline systolic 
blood pressure was 90 mmHg in the dobutamine group and 95 
mmHg in the nitroprusside group; there is no indication whether 
this difference was significant. Heart transplantation was done in 
78 % of those on dobutamine and only in 48% of those on 
nitroprusside 31.  
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 In 261 patients, in-hospital infusion of nesiritide in two different 
doses was compared with  dobutamine. Six-month mortality was 
lower in the nesiritide groups 32.  
This last study was designed to compare the outcomes in patients with infusion 
of nesiritide in a lower and higher dose versus any other vasoactive drug, at the 
discretion of the investigator, and patients were randomized into these three 
arms. Some patients in the arm with vasoactive drug were on dobutamine. The 
comparison between nesiritide and dobutamine was therefore a comparison 
between non-randomized groups, with very limited number of baseline 
characteristics and no invasive hemodynamic information. Moreover, mean 
baseline systolic blood pressure was 120 mmHg, and blood pressure below 90 
mmHg was an exclusion criterion. Consequently, the study omitted all patients 
with low output HF syndrome, fundamentally excluding the only patients with an 
indication for dobutamine use.  This essential design flaw makes the study 
inconclusive. The study of Capomolla et al. 31 is also inconclusive due to lack of 
randomization.  
Comparison of dobutamine versus milrinone in hospitalized patients, awaiting 
heart transplantation, did not show a clear advantage of one or the other in terms 
of right heart hemodynamics, death, need for additional vasodilator/inotropic 
therapy, need for mechanical cardiac support before transplantation, or 
ventricular arrhythmias requiring increased antiarrhythmic therapy 21. 
Intermittent home infusions 
Historically, intermittent infusions of inotropes were used as a treatment for end 
stage HF with severe symptoms (NYHA III/IV). This practice is no longer 
supported and is a Class III recommendation per ACC/AHA3. We summarized 
the outcomes in our previous article 11. Randomized controlled trials are included 
into Tables 3-5. 
 Continuous home infusions 
 
Continuous inotrope infusion at home is more relevant to today’s practice than 
intermittent treatments. Such infusion may be used to improve symptoms and to 
better quality of life in hospice patients, in addition to acting as a bridge to cardiac 
transplant in candidates awaiting a donor.  A decrease in the need for HF 
hospitalizations after initiation of continuous home inotrope infusions was 
suggested by the analysis of the Medicare data 33. 
 
 Continuous home infusion of dobutamine or milrinone in 24 and 7 
patients, respectively, resulted in improvement in NYHA functional 
class from 4.0+/-0.0 to 2.7+/-0.9 (p<0.0001), decrease of number 
of hospital admissions and length of stay from 20.9+/-12.7 to 
5.5+/-5.4 days (p=0.0004), as well as a 16% reduction in cost of 
care in comparison to control period preceding the therapy 34. 
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 Continuous home infusion of milrinone was used in 60 heart 
transplant candidates and resulted in hemodynamic and 
symptomatic improvement as well as cost reduction, with 88.3% of 
patients eventually undergoing heart transplant 35. 
  
 Continuous home infusion of milrinone was given to 29 heart 
transplant candidates and resulted in hemodynamic and 
symptomatic improvement 36 
 
 Continuous home infusion of milrinone (8 patients) or dobutamine 
(12 patients) given as a bridge to cardiac transplantation, resulted 
in improvement of functional status, serum creatinine, better 
hemodynamic parameters, and decreased number of 
hospitalizations during positive inotropic infusion therapy when 
compared with pre-treatment baseline 37 
 
 Continuous home infusion of dobutamine (4 patients), dopamine 
(13 patients), or the combination of both (6 patients) resulted in 
reduction of the number of days spent in the hospital 38  
 
 Continuous (4 patients) and intermittent (7 patients) home infusion 
of dobutamine in 11 patients resulted in symptomatic improvement 
39 
 
    
The number of reported deaths while on inotropes varied greatly among the 
studies, but since there were no control groups, and same patients’ historical 
data were used as control, no conclusion about mortality can be derived.  
 
Mortality Data and Randomized Studies 
 There is a relative paucity of randomized control studies on the mortality 
effect of inotropes in HF.  Thus, to date, much of the data on the subject has 
been drawn from retrospective analysis.  Overall, the data suggests that mortality 
of patients treated with intravenous inotropes is high. In the Evaluation Study of 
Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness 
(ESCAPE) trial, six month mortality in patients with HF receiving inotropes during 
hospitalization reached 19% 40, while the analysis of the Medicare data indicated 
that in patients treated with continuous home inotrope infusion, a six month 
mortality exceeded 40% 33. Analysis of the Acute Decompensated Heart Failure 
National Registry (ADHERE), showed that inotropic treatment with dobutamine 
and milrinone was associated with a 200% increase of in-hospital mortality in 
comparison to vasodilators 41.  However, baseline characteristics of the patients 
on inotropes, such as systolic blood pressure over 120 mmHg, demonstrate that 
they did not have low output syndrome. Only 8% of patients, started on 
inotropes, had systolic blood pressure less than 90 mmHg.  
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 Moreover, the Flolan International Randomized Survival Trial (FIRST), 
determined that six month mortality among patients on dobutamine was 70%, 
with dobutamine being the strongest independent predictor of mortality in the 
study 42. Use of dobutamine or milrinone was consistent with very poor 
prognosis, even in comparison with other intravenous vasoactive drugs like 
vasodilators 41. The addition of more than one inotrope is associated with further 
mortality increase 43.  High mortality rate alone, however, does not in itself prove 
that inotropes are detrimental.  Indeed, mortality is expected to be high by virtue 
of the advanced disease states in those who require inotropes.   
 
 Meta-analyses and retrospective analyses examining the mortality effect 
of inotropes in HF have been largely mixed.  A meta- analysis of multiple 
placebo-controlled trials by Thakray et al. 44 failed to demonstrate increased 
mortality on inotropes, while another meta-analysis on phosphodiestherase-3 
inhibitors showed poorer outcomes on these agents 45. In another retrospective 
study, no mortality difference was found between dobutamine and milrinone at 
home in a single center experience 46, although milrinone was deemed more 
effective as a bridge to transplant, allowing more patients to be bridged by 
inotropes alone, without the need for mechanical circulatory support. Also, renal 
and hepatic function improved on milrinone 47. 
Some suggestions of increased mortality on inotropes come from post-hoc 
analyses of trials not designed to test the outcomes on inotropes where no 
randomization on inotrope versus no inotrope or placebo was conducted. For 
example, the FIRST trial was a randomized, controlled trial, designed to test the 
effects of continuous intravenous epoprostenol plus conventional therapy versus 
conventional therapy alone in patients with advanced HF. Some patients who 
entered the trial were also on intravenous dobutamine 42. The analysis of the 
outcomes depending on the use of dobutamine is therefore flawed because the 
patients who required inotropes were sicker (89% in NYHA IV) than those who 
did not (53%).  
 
 We grouped the randomized trials on inotropes into three categories: 
trials that demonstrate negative effects of inotropes on clinical outcomes, those 
that show neutral effects, and those that show beneficial effects of inotropes 
(Table 3). 
 
 Increased mortality was found on oral enoximone 48,49, oral vesnarinone 
50, oral ibopamine 51, oral milrinone 51,52, and beta agonist xamoterol. 
Vesnarinone was associated with a dose-dependent increase in mortality mostly 
due to arrhythmic death 50. None of these inotropes is currently in use, for the 
very reason of being associated with high mortality, and hence none of these 
outcomes are pertinent to the effects of intravenous dobutamine or milrinone. 
Besides, inotropes are proarrhythmic, and sudden cardiac death is considered 
the main mechanism responsible for excess mortality on inotropes 50. Meanwhile, 
all the above studies were conducted before the time when implantation of 
automatic cardioverters-defibrillators had become the routine.  Today, many of 
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the patients on inotropes are implanted with defibrillators by the time they are 
inotrope dependent, and they are largely protected from arrhythmic death. 
 Indirectly, this consideration is confirmed by the study of Drakos et al.  
Due to concern that arrhythmia might contribute to inotrope-induced mortality, 
they compared end stage HF patients on intermittent inotropes versus 
conventional medical management, adding oral amiodarone to both groups 
(inotropes were represented by either dobutamine or levosimendan). The study 
was not randomized. The 6-month (51% versus 18%) and 1-year (36% versus 
9%) survival rates were significantly higher (p = 0.001 for both), and functional 
status was better, in patients on inotropes and amiodarone 53. Earlier, the same 
group of authors demonstrated similar results in a randomized placebo controlled 
study (see Tables 3-5) 54.   
 The majority of randomized studies are neutral demonstrating neither 
benefit nor detriment of inotropes.  In the Outcomes of a Prospective Trial of 
Intravenous Milrinone for Exacerbations (OPTIME-CHF) trial of 951 patients 
admitted for acute decompensated HF, there were no significant differences of in 
hospital mortality, 60 day mortality or combined 60 day death when comparing 
milrinone versus placebo 55.  Post hoc subgroup analysis did reveal an increase 
in a composite of death or re-hospitalization  in patients with coronary artery 
disease treated with milrinone versus placebo (42% versus 36%), although no 
difference was found between the two groups in non-ischemic patients 56.  The 
ESSENTIAL trial examined the effect of low dose enoximone on patients with 
advanced HF on optimal medical therapy, and also showed no mortality 
difference 57. In another study, oral enoximone used for weaning from 
intravenous inotropes, did not affect the mortality 58. Other authors 59-65 also 
reported no difference in terms of mortality between inotropes and placebo. 
 Conversely, relatively few studies demonstrated beneficial effects of 
inotropes on mortality. Similarly to those trials showing increased mortality, most 
studied agents are not currently in use and therefore not very pertinent: 
enoximone 58,66, vesnarinone 67, amrinone 68. The only study on dobutamine in 
this group used it in combination with amiodarone to negate potential 
proarrhythmic effects. Mortality reduction on dobutamine plus amiodarone versus 
placebo plus amiodarone had hazard ratio of 0.403 (95% confidence intervals 
0.164 -0.992; p = 0.048). 
 But the main observation from reading reports of inotrope use, 
randomized or not randomized, is that very few authors report the data on central 
hemodynamics. We saw in multiple sets of guidelines cited in the beginning of 
this review that the only indication for inotropes in HF is low output syndrome. 
Meanwhile, very few papers provide hemodynamic data. It means, that in most 
studies, cardiac index/cardiac output were not even measured, and patients were 
enrolled based on symptomatic HF and decreased left ventricular ejection 
fraction, which is not an equivalent for low output syndrome. Moreover, in the 
OPTIME-CHF trial, patients were excluded if their doctors thought that inotropes 
were indicated 55.  Therefore, the effects of inotropes were tested on patients 
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who did not have indications for them, which is the best way to evaluate for side 
effects without therapeutic benefits. 
 In summary, most randomized controlled trials with inotropes share 
following features: 
 They were performed with pharmacologic agents that are currently 
not in use. The reason for them being no longer used is the fact 
that they increase mortality. This does not mean, however, that 
the effects of the drugs, which proved to be detrimental, can be 
extrapolated to currently used agents. 
 They were performed in the years when automatic cardioverters-
defibrillators were not recommended for primary prevention, and 
an excess of sudden death may not be pertinent to current 
situation when the patients with advanced cardiomyopathy are 
protected with implanted defibrillators. 
 They were performed on patients who did not have any evidence 
of low output syndrome and therefore did not have indications for 
inotropes. 
  
Conclusions 
Randomized controlled trials with inotropes share certain common features: they 
were performed with inotropes that are not currently in use; they were performed 
before the time when automated cardioverter-defibrilators became standard of 
care for primary prevention of sudden cardiac death; and they were performed on 
patients without evidence of low output heart failure and without indications for 
inotropes.  Thus, these studies may not be generalizable to our current clinical 
practice. 
Currently, there is no evidence to suggest that in patients with low output 
syndrome, treated according to the current guidelines, and protected by 
implantable cardioverters-defibrillators, inotropes increase mortality. To the 
contrary, recognition of the state of inotrope dependency is incompatible with the 
statement that inotropes increase mortality.  
.   
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Table 3. Randomized control trials of inotropes in heart failure: poor outcomes of inotropes 
Source, design N Follow-up Inotrope Cardiac 
index at 
baseline 
Mortality Other Outcomes in the 
Inotrope group versus 
Placebo 
Cohn et al, 1998 53 
Vesnarinone Trial, 
randomized to 
vesnarinone in two 
different doses and 
placebo 
3833   
  
286 days  
Vesnarinone, 
oral   
Not 
reported 
Mortality: 
Vesnarinone lower dose: 
21%  
Vesnarinone higher 
dose: 22.9%  
Placebo: 18.9%,  p<0.02 
(versus placebo), the 
difference is presumably 
due to sudden 
(arrhythmic) death. 
Improved quality of life 
Cowley et al., 1994 52 
The Enoximone trial 
A randomized, double 
blind, placebo controlled 
trial: Enoximone vs 
placebo   
151 
   
One year Enoximone, 
oral 
Not 
reported 
Number of deaths: 
Enoximone: 27 
Placebo: 18, p<0.05 
 
Sudden deaths: 
Enoximone: 11 
Placebo: 5 
Progressive HF death: 
Enoximone: 12 
Placebo: 11 
The trial was ended 
early  because of an 
excess mortality in the 
patients 
treated with enoximone 
Improved quality of life   
Uretsky et al.,  1990  51 
Enoximone trial 
Double-blind, 
randomized, placebo-
controlled 
Enoximone vs placebo 
102 4 months Enoximone, 
oral 
Not 
reported 
Mortality: 
Enoximone: 5 patients 
Placebo: 0 patients, 
p<0.05 
Two deaths were 
sudden, two were from 
progressive HF, and one 
was from acute 
myocardial infarction. 
 
No differences in 
symptoms or exercise 
duration at the end of 4 
months.   
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Hampton et al., 199754 
Randomized, placebo-
controlled 
Ibopamine vs placebo 
1906   About one 
year 
Ibopamine, 
oral 
Not 
reported 
Mortality: 
Ibopamine: 232 (25%) 
Placebo:193 (20%)  
Relative risk 1.26 [95% 
CI 1.04-1.53], p = 0.017. 
The trial was stopped 
early, because of an 
excess of deaths in the 
ibopamine group 
  
Packer et al., 1991 
55 
Prospective 
Randomized Milrinone 
Survival Evaluation 
(PROMISE) trial 
Double blind, 
randomized 
Oral milrinone vs 
placebo 
 
1 088     6 months Oral 
milrinone 
Not 
reported 
Mortality from all 
causes: 
Milrinone: 30% 
Placebo: 24% 
A 28 % increase in all 
cause mortality, p = 
0.038, and a 34% 
increase in 
cardiovascular mortality, 
p = 0.016).   The trial 
stopped prematurely 
because of survival 
compromise on 
milrinone. 
Hospitalizations: 
Milrinone 44% 
Placebo 39%,  p = 0.041  
The Xamoterol in 
Severe Heart Failure 
Study, 1990 74.  
Randomized, double-
blind, placebo-controlled 
Randomization: 
xamoterol vs placebo 
516   13 weeks Xamoterol, 
oral (beta 
receptor 
agonist) 
Not 
reported 
Mortality: 
Xamoterol 9.1% 
Placebo: 3.7%, p=0.02  
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Table 4. Randomized control trials of inotropes in heart failure: neutral outcomes of inotropes 
Source, design N Follow-up Inotrope Cardiac 
index at 
baseline 
Mortality Other Outcomes in the 
Inotrope group versus 
Placebo 
Cuffe et al., 2002 58 
Outcomes of a 
Prospective Trial of 
Intravenous Milrinone for 
Exacerbations 
(OPTIME-HF) trial: 
randomized, double-
blind, placebo-
controlled. 
Milrinone vs placebo 
951   60 days IV milrinone Not 
reported 
In-hospital mortality  
Milrinone: 3.8%  
Placebo: 2.3% 
60-day mortality  
Milrinone: 10.3%  
Placebo: 8.9% 
No difference 
Composite incidence of 
death or readmission: no 
difference 
Milrinone: 35%  
Placebo: 35.3% 
 
The median number of 
days hospitalized for 
cardiovascular causes 
within 60 days after 
randomization: 
No difference 
Metra et al., 2009 60 
The Studies of Oral 
Enoximone Therapy in 
Advanced HF 
(ESSENTIAL), two 
identical, randomized, 
double-blind, placebo-
controlled trials differed 
only by location 
1854      17 months 
 
Enoximone, 
oral 
Not 
reported 
All-cause mortality: no 
difference 
  
The 6 minute walk distance 
increased with enoximone, 
compared with placebo, in 
ESSENTIAL-I (p = 0.025, 
not reaching, however, the 
pre-specified criterion for 
statistical significance of p< 
0.020  
Colucci et al., 1993 62 
Two randomized 
placebo controlled trials: 
milrinone vs placebo 
140   
 
3-6 
months 
Milrinone, 
oral 
Not 
reported 
No mortality difference. 
Trials terminated 
prematurely because of 
the release of the 
unfavorable results of 
the other trial 
Improved exercise capacity 
on milrinone  
  
Dibianco et al., 1984 75 
Randomized double-
blind withdrawal study  
Patients who responded 
to amrinone in the first 
phase of the trial, were 
randomized to continue 
amrinone or to change 
to placebo 
52  3 months 
 
  
 
Not 
reported 
 No difference in cardiac 
performance or in 
rehospitalizations or 
functional status 
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Elis et al., 1998 63  
Randomized, double 
blind, placebo controlled 
Dobutamine vs placebo 
over a 24-hour period 
every 2 to 3 weeks. 
19   6 months   Dobutamine 
IV, 
intermittent  
Not 
reported 
The median survival  
Dobutamine: 4.6 months 
Placebo 8 months 
No difference 
  
No  difference  between the 
number of admissions for 
HF   
Erlemeier et al., 1992  64   
Dobutamine vs placebo 
20  4 weeks Dobutamine, 
IV 
intermittent 
Not 
reported 
No mortality difference Dobutamine: exercise 
duration increase, body 
weight decreased 
Placebo: no change 
 Oliva et al., 1999 66 
DICE 
(Dobutaminanell'Insuffici
enza Cardiaca) trial:   
Dobutamine vs standard 
treatment 
38 
      
6 months  IV 
dobutamine, 
intermittent 
1.89 +/- 
0.1 
L/min/m(
2) 
Dobutamine: 5 deaths, 2 
heart transplants 
Standard treatment: 3 
deaths. 
No difference 
Hospitalizations for all 
causes: no difference 
Dobutamine: 11 (7 for HF) 
Standard treatment: 17 (11 
for HF) 
No difference in NYHA 
class and in 6-minute 
walking test. 
Massie et al., 1985 65 
Double-blind, placebo-
controlled  
Amrinone vs placebo 
99 12 weeks Amrinone, 
oral 
Not 
reported 
No mortality difference Exercise tolerance: no 
difference 
   
Narahara, 1991 67 
The Western Enoximone 
Study 
Randomized, placebo 
controlled 
Enoximone vs placebo 
164  12 weeks Enoximone, 
oral 
Not 
reported 
 No mortality difference Enoximone: greater 
increases in exercise time 
than placebo treatment at 
weeks 4 and 8  but not 
after 12 weeks.   
Van Veldhuisen et al., 
1993 68 
The Dutch Ibopamine 
Multicenter Trial 
Double-blind placebo-
controlled, randomized 
Ibopamine vs digoxin vs 
placebo 
161   6 months Ibopamine, 
oral 
  
 Not 
reported 
No mortality difference 
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Table 5. Randomized control trials of inotropes in heart failure: good outcomes of inotropes 
Source, design N Follow-up Inotrope Cardiac 
index at 
baseline 
Mortality Other Outcomes in the 
Inotrope group versus 
Placebo 
Dubourg et al., 1990  69 
A double-blind, 
randomized  trial 
Enoximone vs. placebo     
30 31 days Enoximone, 
oral 
2.17 +/- 
0.7 
L/min/m2 
Mortality 
Enoximone: 1 
Placebo: 3 
Symptoms improvement on 
enoximone  
Feldman et al, 2007 61. 
EMOTE trial 
(Enoximone in 
Intravenous Inotrope-
Dependent Subjects 
Study 
Enoximone or placebo. 
Enoximone was used to 
wean patients from IV 
inotropes 
   
201   
   
6 months Oral 
enoximone   
Not 
reported 
Alive and free of IV 
inotropes at 30 days   
Enoximone: 62 (61.4%) 
Placebo: 51 (51%)  
At 60 days 
Enoximone: 46.5% 
Placebo: 30%,  
p = 0.016 
Time to death or re-
initiation of IV inotropes  
At 6 months: 
HR 0.76 [95% CI 0.55-
1.04])  
At 60 days: 
HR 0.62 [95% CI 0.43-
0.89], p = 0.009   
At 90 days: 
HR 0.69 [95% CI 0.49-
0.97], p = 0.031, 
favoring enoximone.  
 
Feldman et al., 1993 70 
Vesnarinone Study 
Randomized, double-
blind, placebo-controlled 
 Vesnarinone  vs 
placebo 
477 6 months Vesnarinone, 
oral 
Not 
reported 
Mortality plus worsening 
HF: 
Vesnarinone:26 
Placebo: 50, p= 0.003 
A 62 % reduction (95% 
CI, 28 - 80 %) in the risk 
of dying from any cause 
Vesnarinone: quality of life 
improved to a greater 
extent than in the placebo 
group over 12 weeks (P = 
0.008) 
Page 12F 
  among the patients 
receiving vesnarinone 
Nanas et al., 2004 57   
Randomized, double-
blind, placebo-controlled 
clinical trial. 
Dobutamine vs placebo 
   
 
 30 
 
6 months 
 
Dobutamine, 
IV 
Intermittent, 
plus 
amiodarone   
2.3 ± 0.7 
L/min/m(
2) 
Survival 
Dobutamine plus 
amiodarone vs placebo 
plus amiodarone 
HR=0.403; 95% CI= 
0.164 -0.992; p = 0.048 
1-year survival estimate 
Dobutamine plus 
amiodarone: 69% 
Placebo plus 
amiodarone:28%, 
p<0.05 
2-year survival estimate 
Dobutamine plus 
amiodarone: 44% 
Placebo plus 
amiodarone: 21%, 
p<0.05 
  
Likoff et al., 1984 71 
Randomized, double 
blind, placebo controlled 
After being stabilized on 
amrinone, patients were 
randomized into 
continuation on 
amrinone or withdrawal 
of amrinone 
9     Two 13 
week 
stages 
Amrinone, IV 1.9+/-
0.2L/min/
m2 
 Placebo: 7 patients  had a 
significant deterioration of 
symptoms or exercise 
tolerance, or both. After 4 
weeks of readministration 
of amrinone, clinical status 
improved 
Khalife et al., 1987 76 
Double-blind, 
randomized, placebo 
controlled 
Randomization: after the 
first phase when IV 
enoximone was given to 
all patients, they were 
randomized into oral 
Enoximone or placebo.  
17 12 weeks Enoximone, 
IV and oral, 
in a 2-part 
study 
3.42 +/- 
0.72 
L/min/m2 
(after 
Enoximo
ne IV) 
 Enoximone: left ventricular 
ejection fraction improved 
from 30.1 +/- 6.8% to 33.9 
+/- 9.9%  
Placebo: unchanged 
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